Alexander Shabliy, a former challenger for the Bellator lightweight title, has received and accepted a six-month suspension from the U.S. Anti-Doping Agency (USADA). This action follows a positive result for a prohibited substance found in an out-of-competition drug test.
USADA officials publicly disclosed the suspension on Wednesday.
According to a statement from USADA officials, the 32-year-old Shabliy tested positive for recombinant erythropoietin (rEPO) based on an out-of-competition sample collected on March 19, 2025. rEPO is classified as a Peptide Hormone, Growth Factor, Related Substance, or Mimetic and is strictly forbidden at all times under the PFL Anti-Doping Policy (ADP) and Prohibited List.
USADA`s statement also explained the duration of the ban. While the standard penalty for using a prohibited substance under Section 10.2 of the PFL ADP is six months, it can extend up to a year in specific situations. However, USADA`s investigation indicated that Shabliy`s use wasn`t intentional, and he significantly assisted in identifying the person who provided the EPO. Consequently, Shabliy received the six-month suspension, which started on March 19, 2025, the day the positive sample was taken.
With the suspension now in effect, Shabliy is expected to become eligible to compete again following Sept. 19th.
Recombinant erythropoietin is prohibited for athletes year-round because this synthetic drug artificially boosts red blood cell production. This increase improves the body`s ability to transport oxygen, offering a clear advantage in terms of cardio and overall conditioning, particularly crucial for fighters.
Shabliy, now competing in the PFL, last fought in September 2024, where he lost a decision to lightweight champion Usman Nurmagomedov. Due to this suspension, he will be sidelined and unable to compete until at least September 2025.
